Protein Synthesis and Degradation
ERp29 Regulates ΔF508 and Wild-type Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Trafficking to the Plasma Membrane in Cystic Fibrosis (CF) and Non-CF Epithelial Cells*

https://doi.org/10.1074/jbc.M111.240267Get rights and content
Under a Creative Commons license
open access

Sodium 4-phenylbutyrate (4PBA) improves the intracellular trafficking of ΔF508-CFTR in cystic fibrosis (CF) epithelial cells. The underlying mechanism is uncertain, but 4PBA modulates the expression of some cytosolic molecular chaperones. To identify other 4PBA-regulated proteins that might regulate ΔF508-CFTR trafficking, we performed a differential display RT-PCR screen on IB3-1 CF bronchiolar epithelial cells exposed to 4PBA. One transcript up-regulated by 4PBA encoded ERp29, a luminal resident of the endoplasmic reticulum (ER) thought to be a novel molecular chaperone. We tested the hypothesis that ERp29 is a 4PBA-regulated ER chaperone that influences ΔF508-CFTR trafficking. ERp29 mRNA and protein expression was significantly increased (∼1.5-fold) in 4PBA-treated IB3-1 cells. In Xenopus oocytes, ERp29 overexpression increased the functional expression of both wild-type and ΔF508-CFTR over 3-fold and increased wild-type cystic fibrosis transmembrane conductance regulator (CFTR) plasma membrane expression. In CFBE41o− WT-CFTR cells, expression of and short circuit currents mediated by CFTR decreased upon depletion of ERp29 as did maturation of newly synthesized CFTR. In IB3-1 cells, ΔF508-CFTR co-immunoprecipitated with endogenous ERp29, and overexpression of ERp29 led to increased ΔF508-CFTR expression at the plasma membrane. These data suggest that ERp29 is a 4PBA-regulated ER chaperone that regulates WT-CFTR biogenesis and can promote ΔF508-CFTR trafficking in CF epithelial cells.

Cystic Fibrosis
Endoplasmic Reticulum (ER)
Epithelial Cell
Ion Channels
Trafficking
4-Phenylbutyrate
CFTR
ERp29

Cited by (0)

*

This work was supported, in whole or in part, by National Institutes of Health Grants R01 DK058046 and R01 DK073185 from the NIDDK (to R. C. R.), R01 HL059959 (to S. G.) and K08 HL081080 from the NHLBI (to J. L. K.), and T35 HD0744 (a student research fellowship to L. A. through the American Pediatric Society-Society for Pediatric Research). This work was also supported by grants from the Pennsylvania-Delaware Chapter of the American Heart Association (to L. S.) and the Cystic Fibrosis Foundation (to R. C. R.).

1

Supported by Lottery Health Research New Zealand and a professorial fellowship from the Melbourne Research Unit for Facial Disorders.